| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000017080 |
| Receipt No. | R000019814 |
| Scientific Title | Survey of vulvar cancer in Japan |
| Date of disclosure of the study information | 2015/04/08 |
| Last modified on | 2020/02/05 (Ver. 6) |
| Basic information | ||
| Public title | Survey of vulvar cancer in Japan | |
| Acronym | JGOG1075S | |
| Scientific Title | Survey of vulvar cancer in Japan | |
| Scientific Title:Acronym | JGOG1075S | |
| Region |
|
|
| Condition | ||
| Condition | Vulva Cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To conduct a survey of vulvar cancer in Japan to clarify patient characteristics and the current status of treatment regimens and thereby obtain useful information for planning future prospective clinical studies of vulvar cancer |
| Basic objectives2 | Others |
| Basic objectives -Others | Retrospective observational study |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | To conduct a survey of vulvar cancer in Japan to clarify patient characteristics and the current status of treatment regimens and thereby obtain useful information for planning future prospective clinical studies of vulvar cancer |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | (1) Patients who received treatment for vulvar cancer during the 10-year period from January 2001 through December 2010, including those who initially received palliative therapy
(2) Primary vulvar cancer, not including metastatic vulvar cancer (3) All histologic types other than malignant melanoma |
|||
| Key exclusion criteria | Malignant melanoma | |||
| Target sample size | 1000 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kurume University School of Medicine | ||||||
| Division name | Department of Obstetrics and Gynecology | ||||||
| Zip code | 830-0011 | ||||||
| Address | 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan | ||||||
| TEL | 0942-31-7573 | ||||||
| shinshin@med.kurume-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kurume University School of Medicineurume University School of Medicine | ||||||
| Division name | Department of Obstetrics and Gynecology | ||||||
| Zip code | 830-0011 | ||||||
| Address | 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan | ||||||
| TEL | 0942-31-7573 | ||||||
| Homepage URL | |||||||
| shinshin@med.kurume-u.ac.jp | |||||||
| Sponsor | |
| Institute | Japanese Gynecologic Oncology Group (JGOG) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japanese Gynecologic Oncology Group (JGOG) |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Kurume Univeristy |
| Address | 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan |
| Tel | 0942-35-3311 |
| sangaku@kurume-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Partially published |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | 1. Methods
The survey variables described in Study variables will be entered into Excel worksheets. Excel files will be sent as disks by mail. After data entry, the completed survey questionnaires will be returned to the Study Secretariat by means of self-addressed envelopes. 2. Survey variables a. Patient characteristics Age, history of pregnancy and delivery, disease stage (FIGO2008), HPV high-risk tests, HPV typing tests, histologic type, tumor diameter, initial treatment, date of starting treatment, date of completing treatment, presence or absence of recurrence, date of confirming recurrence, treatment for recurrence, survival status, final date of confirming survival b. Surgical therapy Vulva: Extensive total vulvectomy, radical partial vulvectomy, sentinel lymph-node dissection Inguinal region: Unilateral, bilateral shallow inguinal lymph-node dissection, shallow/deep inguinal lymph-node dissection, en bloc method, and separate incision method Reconstruction: Partial skin grafting, cutaneous flap, and myocutaneous flap Complications: Evaluation of the incidences and grades of wound dehiscence, edema, infectious lymphangitis, thrombosis, and urinary-tract infection c. Radiotherapy Preoperative, initial, and postoperative radiotherapy: Radiotherapy alone (radiation fields, radiation methods [curative radiation and palliative radiation], Linac, electron beams, total radiation dose, treatment duration, completion rate) Preoperative, initial, and postoperative chemoradiotherapy: (Radiation fields, radiation methods, Linac, electron beams, total radiation dose, treatment duration, regimen, number of courses, completion rate), adverse events (including late toxicity) d. Chemotherapy Preoperative, initial, and postoperative chemotherapy: regimens, number of courses, adverse events 3. Number of patients and study period Survey period: from August 1, 2014 through March 31, 2015 Target number of patients: 1000 |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000019814 |